biotechnology
1 min read
Roivant’s Brepocitinib Phase 3 Dermatomyositis Trial Hits Primary and All Key Secondary Endpoints
Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best stocks to buy under $20. On September 17, Roivant and Priovant Therapeutics announced positive results from the Phase 3 VALOR study, a 52-week placebo-controlled trial evaluating the once-daily oral drug brepocitinib in patients with dermatomyositis/DM. This trial enrolled 241 subjects globally and is noted as the […]